文献速递治疗药物监测与药物基因组学

英国公众对NHS药物基因组学检测服务的偏好:将离散选择实验嵌入服务设计

Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs.
PubMed 文献 · Br J Clin Pharmacol · 2024-04-14

本研究通过在线调查1993名英国公众,采用离散选择实验量化其对初级保健药物基因组学检测服务的偏好。条件logit和潜在类别分析显示,公众偏好无创检测、数据在医疗机构间共享(尤其区域共享)及可访问自身数据。不同服务设计下预测接受率从51%至>99%不等。

要点

  • 公众偏好无创药物基因组学检测及区域而非全国数据共享。
  • 服务设计微调可使预测接受率在51%至>99%间变化。
  • 情绪低落与疼痛两种临床场景下偏好无差异。

核心结论

  • 公众对药物基因组学检测服务的偏好可量化,且预测接受率受服务设计细节显著影响。

研究设计与样本

  • 通过在线面板公司调查英国公众,完成两种版本问卷之一,涉及情绪低落或疼痛场景下的药物基因组学检测服务选择。
  • 共1993名个体纳入分析,采用条件logit模型及潜在类别分析识别偏好异质性。

主要发现

  • 条件logit分析(最大似然估计)表明受访者偏好无创检测及数据在医疗机构间共享以指导未来处方。
  • 受访者偏好区域而非全国数据共享倡议,并希望可访问自身数据。
  • 两种临床场景间未观察到偏好差异。
  • 预测接受率范围51%至>99%,取决于服务设计。

临床怎么用

  • 未来药物基因组学服务开发应优先考虑无创检测方式、区域数据共享及患者数据访问。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Genetic testing can be used to improve the safety and effectiveness of commonly prescribed medicines-a concept known as pharmacogenetics. This study aimed to quantify members of the UK public's preferences for a pharmacogenetic service to be delivered in primary care in the National Health Service. METHODS: Members of the UK population were surveyed via an online panel company. Respondents completed 1 of 2 survey versions, asking respondents to select their preferred pharmacogenetic testing service in the context of a presentation of low mood or pain. A conditional logit model was estimated, before the best functional form for the dataset was identified. Preference heterogeneity was identified via latent class analysis. Coefficients from the final selected models were used to estimate uptake in the context of different hypothetical pharmacogenetic services. RESULTS: Responses from 1993 individuals were included in the analysis. There were no differences observed in preference between the 2 clinical scenarios. Conditional logit analysis, using maximum likelihood estimation, indicated that respondents preferred to have noninvasive tests and wanted their data to be shared between different healthcare organizations to guide future prescribing. There was a preference for regional over national data sharing initiatives, and respondents preferred to have access to their data. Predicted uptake varied considerably, ranging from 51% to >99%, depending on design of the service. CONCLUSION: This study identifies public preferences for a pharmacogenetic testing service and demonstrates how predicted uptake can be impacted by relatively minor adaptations. This highlights areas for prioritization during development of future pharmacogenetic services.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. McDermott JH, Sharma V, Newman WG, et al. Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs. Br J Clin Pharmacol. 2024. PMID: 38616172. doi:10.1111/bcp.16058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。